P4‐225: A confirmatory phase 3 randomized, double‐blind, placebo‐controlled study of the safety and effectiveness of immune globulin intravenous (Human), 10% solution (GAMMAGARD LIQUID/KIOVIG) for the treatment of mild to moderate Alzheimer's disease